Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M1231 in advanced solid tumors
NCT04695847Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Jan 2021
- Primary completion
- Jun 2023
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of M1231 in solid tumor (advanced stage) and Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by EMD Serono. Primary endpoints: Dose Limiting Toxicities, Treatment Emergent Adverse Events at 6 months and 2 more. Started Jan 2021; status: completed.
02
Drugs
M1231
03
Conditions
solid tumor (advanced stage)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04695847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695847.